Trevena (NASDAQ:TRVN) Shares Cross Below 200 Day Moving Average – Time to Sell?

Trevena, Inc. (NASDAQ:TRVN) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.03 and traded as low as $1.58. Trevena shares last traded at $1.77, with a volume of 1,175 shares.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. StockNews.com initiated coverage on shares of Trevena in a report on Thursday. They issued a “sell” rating on the stock. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Trevena in a research note on Thursday, November 14th.

Trevena Price Performance

The firm has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.04 and a beta of 1.05. The stock has a 50 day moving average price of $1.70 and a two-hundred day moving average price of $3.03.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The business had revenue of $0.28 million during the quarter. As a group, research analysts expect that Trevena, Inc. will post -23.04 earnings per share for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.